(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of 126.15% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Entrada Therapeutics's revenue in 2026 is $4,686,000.On average, 10 Wall Street analysts forecast TRDA's revenue for 2026 to be $670,995,617, with the lowest TRDA revenue forecast at $68,684,284, and the highest TRDA revenue forecast at $2,044,175,123. On average, 10 Wall Street analysts forecast TRDA's revenue for 2027 to be $1,509,341,037, with the lowest TRDA revenue forecast at $136,239,405, and the highest TRDA revenue forecast at $3,066,262,684.
In 2028, TRDA is forecast to generate $2,051,144,786 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $7,154,612,929.